BioProcess International
 
 

Webcast Information


 

Navigating the Biopharmaceutical Regulatory Pathway:
Replacing Undefined Raw Materials with Chemically-defined Substitutes

With market demands increasing, biopharmaceutical producers are constantly looking for ways to enhance product quality while reducing costs and risk. One way to meet these changing demands is to replace animal-derived supplements with chemically-defined substitutes. In this educational webcast, Dr. Michael Titus, Director of Quality Management and Regulatory Compliance with BD Biosciences, outlines the regulatory pathway involved in making such a switch. Dr. Titus will discuss:

  • A background on the uses of supplements in the cell culture production process;
  • Change control & risk management;
  • And the regulatory path of making the switch to chemically-defined supplements.

Join Dr. Titus as he demonstrates how chemically-defined supplements can boost performance, reduce risk and increase consistency in commercially marketed biopharmaceutical products.

 

View Webcast Download PDF

 
 

Targeted BPI Content
 

Disposable Downstream Processing for Clinical Manufacturing
BioProcess International, May 2011
Read more. 

 

Maintaining Product Titer While Replacing Undefined Components in a CHO Culture System
BioProcess International, September 2009
Read more.

 

Practical Considerations for DoE Implementation in Quality By Design
BioProcess International, June 2010
Read more.

 

Raw Material Control Strategies for Bioprocesses
BioProcess International, September 2009
Read more. 

 

Changes in Raw Material Sources from Suppliers
BioProcess International, April 2010
Read more. 

 

Measuring Manufacturing Cost and Its Impact on Organizations
BioProcess International, June 2010
Read more. 
 

Powered by Powered by PropelMG  
 
 
Visit BioProcess International Home